CD8A and neoplasm: A DDR inhibitor AZD6738 and radiotherapy combined with anti-PD-L1 antibodies could perform better tumor growth inhibition and recurrence prevention by boosting CD8+ T cell infiltration and activation in tumor microenvironment in a mouse model (93).